ClinicalTrials.gg

Program

sonesitatug vedotin

Also written as “AZD0901”, “Sonesitatug Vedotin” and “Sonesitatug vedotin”.

Its studies are mostly in Stomach Neoplasms · Pancreatic Neoplasms, led by 2 companies.

Furthest: phase 3, since Feb 28, 20247 company-led studies, 6 open or runningNext primary completion: Nov 17, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca66 open or runningphase 3since Feb 28, 2024Dec 7, 2022Nov 17, 2026phase 2 · NCT06219941
Keymed Biosciences10 open or runningphase 1since Mar 16, 2021Mar 16, 2021none ahead
  • Named in AstraZeneca’s own pipeline as sonesitatug vedotin, phase 3, as of Oct 30, 2026 (source).

Also a collaborator on its studies: parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 16, 2021First study: phase 1 study in Pancreatic NeoplasmsNew to Keymed BiosciencesKeymed Biosciences · NCT04805307 · 176 enrolled · China
  2. Dec 7, 2022AstraZeneca's first study: phase 2 study in Stomach NeoplasmsNew to AstraZenecaAstraZeneca · NCT05702229 · 163 planned · United States, China, Japan and more
  3. Nov 21, 2023Phase 2 study in Stomach NeoplasmsAstraZeneca · NCT06219941 · 226 planned · United States, Australia, Canada and more
  4. Feb 28, 2024Phase 3 study in Stomach NeoplasmsAstraZeneca · NCT06346392 · 594 enrolled · United States, Brazil, Canada and more
  5. Jun 24, 2025Phase 2 study in Stomach NeoplasmsAstraZeneca · NCT07069712 · 100 planned · United States, Canada, China and more
  6. Aug 20, 2025Phase 2 study in Stomach NeoplasmsAstraZeneca · NCT07143604 · 33 enrolled · Russia
  7. Jan 16, 2026Phase 3 study in Stomach NeoplasmsAstraZeneca · NCT07431281 · 2,130 planned · United States, Australia, Austria and more

Ahead

  1. Nov 17, 2026Primary completion: phase 2 study in Stomach NeoplasmsAstraZeneca · NCT06219941
  2. Nov 9, 2027Primary completion: phase 2 study in Stomach NeoplasmsAstraZeneca · NCT07069712
  3. Nov 30, 2027Primary completion: phase 2 study in Stomach NeoplasmsAstraZeneca · NCT05702229
  4. Aug 16, 2029Primary completion: phase 3 study in Stomach NeoplasmsAstraZeneca · NCT07431281

TargetBeta

“An antibody-drug conjugate (ADC) composed of sonesitatug, a monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), conjugated, via a cleavable linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), w…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of sonesitatug, a monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), ”NCIt, by rule

Other programs on CLDN18

ProgramCompanyFurthest phaseStudies
zolbetuximabruleAstellas Pharmaphase 412
garetatug rezetecanJiangsu HengRui Medicinephase 37
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905ruleQilu Pharmaceuticalphase 36
tecotabart vedotinSino Biopharmaceuticalphase 36
arcotatug tavatecanruleInnovent Biologicsphase 35
terallethrinruleFutureGen Biopharmaceutical (Beijing)phase 33
Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1biokin-shanghai-biopharmaceutical-co-ltdphase 33
emaretamigruleAstellas Pharmaphase 33
Anti-Claudin 18.2 Antibody-drug Conjugate MK-1200ruleSichuan Kelun Pharmaceuticalphase 23
Anti-Claudin 18.2 Antibody-drug Conjugate ASP546CruleAstellas Pharmaphase 22
givastomigrulei-mab-biopharma-us-limitedphase 22
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863AstraZenecaphase 21

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07431281Stomach Neoplasms · United States, Australia, Austria and more3RecruitingAstraZenecaAug 16, 20292,130
NCT07143604Stomach Neoplasms · Russia2Active, not recruitingAstraZenecaAug 14, 202633
NCT07069712Stomach Neoplasms · United States, Canada, China and more2RecruitingAstraZenecaNov 9, 2027100
NCT06346392Stomach Neoplasms · United States, Brazil, Canada and more3Active, not recruitingAstraZenecaMay 31, 2026594
NCT06219941Stomach Neoplasms · United States, Australia, Canada and more2RecruitingAstraZenecaNov 17, 2026226
NCT05702229Stomach Neoplasms · United States, China, Japan and more2RecruitingAstraZenecaNov 30, 2027163
NCT04805307Pancreatic Neoplasms · China1CompletedKeymed BiosciencesApr 5, 2024176

How it is read

Names in the registry

  • “AZD0901”, 5 entries
  • “Sonesitatug Vedotin”, 1 entry
  • “Sonesitatug vedotin”, 1 entry
  • “CMG901”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
sonesitatug vedotin (AstraZeneca): development program | ClinicalTrials.gg